Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
United Therapeutics Corp. (UTHR) PT Raised to $733 at Jefferies
March 30, 2026 10:26 AM EDTJefferies analyst Roger Song raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $733.00 (from $668.00) while maintaining a Buy rating.
The analyst comments "Bottom line. Topline of 2nd Tyvaso Ph3 study for IPF, TETON-1 (US/ Canada) exceeded investors/ our expectations, even better than... More
United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'
March 30, 2026 8:33 AM EDTTD Cowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $660.00 (from $575.00) while maintaining a Buy rating.
The analyst comments "UTHR announced that the second Ph. III study of Tyvaso for IPF (TETON-1) hit the primary... More
